drugset / Trial / NCT07277322

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

NCT07277322

Phase 1/2 Not yet recruiting 24 enrolled Dan Feng Coherus Oncology, Inc. · collab
NaSequentialOpen-labelTreatment

Summary

This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.

Timeline

Start
2026-06-01
Primary completion
2028-12-31
Completion
2030-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous